Oppenheimer analyst Suraj Kalia lowered his price target on Boston Scientific to $65 from $85 on September 21 while maintaining an Outperform rating on the shares. Kalia also cut Oppenheimer's fiscal 2026 estimates, citing the impact of Boston Scientific's eight-day cybersecurity disruption, and reduced fiscal 2027 estimates because of competitive pressures in left atrial appendage closure and electrophysiology. Oppenheimer estimates that roughly 9% of Boston Scientific's revenue-producing days were affected during the breach, which the company disclosed on August 25 and which disrupted manufacturing and order fulfillment until operations were fully restored by September 9. Boston Scientific has said the incident is likely to have a material impact on third-quarter and full-year 2026 results and that it is unlikely to meet the sales-growth and adjusted EPS guidance it issued in July, though the full financial impact is not yet known. The company reported second-quarter revenue of $5.44 billion, up 7.5% year over year on a reported basis and 7% organically, with adjusted EPS of $0.86 versus $0.75 a year earlier, while WATCHMAN global sales grew 4.2% organically and electrophysiology grew 9.1% organically. Boston Scientific plans to provide an updated operational and financial outlook for the remainder of 2026 when it reports third-quarter results on October 28.
Boston Scientific CorpOppenheimer cut its price target to $65 from $85 and lowered FY2026/FY2027 estimates on Boston Scientific.
Oppenheimer Holdings Inc